Citations

Clear

7551 citation(s) found for "Ho, Matthew".

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database
Renfro, Lindsay A. , Goldberg, Richard M. , Sobrero, Alberto , Adams, Richard , Seymour, Michel , Heinemann, Volker , Schmoll, Hans‐Joachim , Douillard, Jean‐Yves , Hurwitz, Herbert I. , Fuchs, Charles S. , Díaz‐Rubio, Eduardo , Porschen, Rainer, Tournigand, Christophe , Chibaudel, Benoist , Hoff, Paulo M. , Kabbinavar, Fairooz F. , Falcone, Alfredo , Punt, Cornelis J.A. , Hecht, J. Randolph, Souglakos, John , Bokemeyer, Carsten , Gramont, Aimery de , Seymour, Matthew T, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Tebbutt, Niall C. , van Cutsem, Eric, Saltz, Leonard, de Gramont, Aimery, Grothey, Axel , Cutsem, Eric Van , Saltz, Leonard B. , Sargent, Daniel J. , Falcone, Alfredo , Seymour, Matthew T , Adams, Richard , Schmoll, Hans-Joachim , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | April 17, 2017 | Volume: 35 | Issue: 17 | Pages: 1929-1937

10.1200/jco.2016.71.5771 | PMID 28414610 Get It

Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled. Multivariable logistic regression models for 30-, 60-, and 90-day mortality were constructed, including clinically and statistically significant patient and disease factors and interaction terms. A calculator (nomogram) for 90-day mortality was developed and validated internally using bootstrapping methods and externally using a 10% random holdout sample from each trial. The impact of early progression on the likelihood of survival to 90 days was examined with time-dependent Cox proportional hazards models. Results Mortality rates were 1.4% at 30 days, 3.4% at 60 days, and 5.5% at 90 days. Among baseline factors, advanced age, lower body mass index, poorer performance status, increased number of metastatic sites, BRAF mutant status, and several laboratory parameters were associated with increased likelihood of early mortality. A multivariable model for 90-day mortality showed strong internal discrimination (C-index, 0.77) and good calibration across risk groups as well as accurate predictions in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectal cancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.
Evaluating Automated Rules for Rapid Response System Alarm Triggers in Medical and Surgical Patients
Morlan, Bruce W., Johnson, Matthew G. , Hickman, Joel , Kirkland, Lisa L., Naessens, James M. , Romero‐Brufau, Santiago , Huddleston, Jeanne M.

Mayo Clinic

Journal of Hospital Medicine | April 15, 2017 | Volume: 12 | Issue: 4 | Pages: 217-223

10.12788/jhm.2712 | PMID 28459899 Get It

BACKGROUNDThe use of rapid response systems (RRS), which were designed to bring clinicians with critical care expertise to the bedside to prevent unnecessary deaths, has increased. RRS rely on accurate detection of acute deterioration events. Early warning scores (EWS) have been used for this purpose but were developed using heterogeneous populations. Predictive performance may differ in medical vs surgical patients.OBJECTIVETo evaluate the performance of published EWS in medical vs surgical patient populations.DESIGNRetrospective cohort study.SETTINGTwo tertiary care academic medical center hospitals in the Midwest totaling more than 1500 beds.PATIENTSAll patients discharged from January to December 2011.INTERVENTIONNone.MEASUREMENTSTime‐stamped longitudinal database of patient variables and outcomes, categorized as surgical or medical. Outcomes included unscheduled transfers to the intensive care unit, activation of the RRS, and calls for cardiorespiratory resuscitation (“resuscitation call”). The EWS were calculated and updated with every new patient variable entry over time. Scores were considered accurate if they predicted an outcome in the following 24 hours.RESULTSAll EWS demonstrated higher performance within the medical population as compared to surgical: higher positive predictive value (P < .0001 for all scores) and sensitivity (P < .0001 for all scores). All EWS had positive predictive values below 25%.CONCLUSIONSThe overall poor performance of the evaluated EWS was marginally better in medical patients when compared to surgical patients.
Advancements in Radiation Techniques for Gastric Cancer
Callister, Matthew D., Gunderson, Leonard L.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 14, 2017 | Volume: 8 | Issue: 4 | Pages: 428-436

10.6004/jnccn.2010.0032 | PMID 20410335 Get It

All but the earliest cases of nonmetastatic gastric cancer represent a therapeutic challenge given the high propensity of these patients to develop locoregional and distant relapse. Neoadjuvant or adjuvant strategies that include chemoradiotherapy or chemotherapy have been associated with significant toxicity, but also improvement in patient survival. Technologic advances in the planning and delivery of radiotherapy (RT) have enabled significant progress in the accuracy and conformality of radiation treatment. Four-dimensional CT and image-guided RT improve the accuracy of radiation treatment. Three-dimensional RT and intensity-modulated RT allow increased conformality of radiation dose distribution, sparing of normal organs, and providing opportunity for dose escalation. Initial clinical experience with these technologies shows favorable tolerance and outcomes.
A cardiovascular prescreening protocol for unmonitored in‐office laryngology procedures
Madden, Lyndsay L. , Ward, Anne , Young, VyVy N. , Smith, Libby J. , Bryson, Paul C. , Clary, Matthew S. , Weissbrod, Phillip A., Bock, Jonathan M. , Blumin, Joel H. , Rosen, Clark A. , Weissbrod, Philip A. , Ward, John , Lott, David G. , Weissbrod, Phil, Clary, Matthew S , Weissbrod, Philip A

Mayo Clinic

The Laryngoscope | April 13, 2017 | Volume: 127 | Issue: 8 | Pages: 1845-1849

10.1002/lary.26481 | PMID 28407258 Get It

ObjectivesCurrently, there are no cardiovascular (CV) preprocedure screening parameters for patients undergoing in‐office laryngeal procedures (IOLP). Studies have shown significant changes in CV measures for IOLP. The aim was to develop and evaluate a pre‐IOLP CV screening protocol.MethodsReview of IOLP literature and consultation with an anesthesiologist and cardiologist led to the development of CV parameters and questions related to four metabolic equivalents (METS) of work as a patient‐screening tool before IOLP. A separate cohort was screened with only a modified CV protocol. All patients were screened for heart rate (HR) and blood pressure (BP) elevation prior to the procedure. Need for further CV evaluation was characterized as systolic blood pressure BP >160, diastolic BP >100, and/or HR >110 beats/minute. Patients whose BP/HR exceeded these values were referred to their primary care physician (PCP) before re‐screening. If parameters were exceeded again at the second screen, then the procedure was done under monitored anesthesia care.ResultsThe first study phase included 56 patients. The fail rate was 40% largely related to four METS of work. The second study phase included 440 patients. The screen fail rate was 15 patients of 572 (2.6%). Of these, 12 patients of 132 (9.1%) failed the initial screen and were sent to their PCP for further evaluation, and five of 440 (1.4%) patients failed on the day of the procedure. Overall, five of 440 (1.5%) patients would qualify to have their site of service changed for their laryngology procedure from an unmonitored to a monitored setting due to the prescreening criteria.ConclusionFew patients needed further workup based upon the in‐office CV parameters set in this study. Patients with CV risk factors were identified by the screening protocol. Having established hemodynamic parameters in place may improve the safety of IOLP with a very low physician burden.Level of Evidence2b Laryngoscope, 127:1845–1849, 2017
Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study
Larsen, Jeremy T. , Leis, José F., LaPlant, Betsy, Call, Tim G., Pettinger, Adam, Hanson, Curtis A. , Erlichman, Charles , Reeder, Craig B. , Nikcevich, Daniel A., Bowen, Deborah A., Conte, Michael, Boysen, Justin C. , Secreto, Charla, Lesnick, Connie , Tschumper, Renee C. , Jelinek, Diane F., Call, Tim, Hanson, Curtis, Habermann, Thomas Matthew, Reeder, Craig, Bowen, Deborah, Boysen, Justin, Tschumper, Renee, Jelinek, Diane, Ding, Wei , Shanafelt, Tait D. , Call, Timothy G., Habermann, Thomas M. , Kay, Neil E. , Ding, Wei

Mayo Clinic

American Journal of Hematology | April 12, 2017 | Volume: 92 | Issue: 8 | Pages: 759-763

10.1002/ajh.24762 | PMID 28402581 Get It

Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK‐2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard phase I design was used with cohorts of three plus three patients to determine the maximum tolerated dose (MTD) of MK‐2206 in combination with BR in relapsed CLL. Single‐agent MK‐2206 (weekly dosed) was administered one‐week in advance before BR on cycle 1 and subsequently was given with BR at the same time for cycle 2‐6. Phase II employed the MTD of MK‐2206 with BR to evaluate safety and efficacy of this study combination. Thirteen relapsed/refractory CLL were treated for maximal 6‐cycle of therapy. The maximum tolerated dose of MK‐2206 was 90 mg by mouth once weekly. The most common grade 3/4 adverse events were neutropenia (46%), febrile neutropenia (23%), rash (15%), diarrhea (15%), and thrombocytopenia (15%). Overall response rate was 92% with a median progression free survival and treatment free survival of 16 and 24 months, respectively. Five patients (38%) achieved complete remission or complete remission with incomplete count recovery, two of whom were MRD negative. The efficacy and tolerability of this combination indicates that Akt inhibition combined with chemoimmunotherapy is a promising novel treatment combination in CLL and deserves further prospective clinical trial.
Facial diplegia after pembrolizumab treatment
Yost, Micah D. , Chou, Claudia , Botha, Hugo , Block, Matthew S. , Liewluck, Teerin , Chou, Claudia Z., Liewluck, T , Botha, Hugo

Mayo Clinic

Muscle & Nerve | April 11, 2017 | Volume: 56 | Issue: 3 | Pages: No page available

10.1002/mus.25663 | PMID 28398689 Get It

Quality of Life in Patients with Vestibular Schwannomas Following Gross Total or Less than Gross Total Microsurgical Resection: Should We be Taking the Entire Tumor Out?
Link, Michael J. , Lund‐Johansen, Morten , Lohse, Christine M. , Driscoll, Colin L. W., Myrseth, Ehrling, Tveiten, Øystein Vesterli , Carlson, Matthew L.

Mayo Clinic

Neurosurgery | April 11, 2017 | Volume: 82 | Issue: 4 | Pages: 541-547

10.1093/neuros/nyx245 | PMID 29554375 Get It

Abstract BACKGROUND The goal of microsurgical removal of a vestibular schwannoma is to completely remove the tumor, to provide long-term durable cure. In many cases, less than gross total resection (GTR) is performed to preserve neurological, and especially facial nerve function. OBJECTIVE To analyze long-term quality of life (QoL) in a cohort of patients who received either GTR or less than GTR. METHODS Patients operated for vestibular schwannoma less than 3.0 cm in posterior fossa diameter at 1 of 2 international tertiary care centers were surveyed using generic and disease-specific QoL instruments. RESULTS A total of 143 patients were analyzed. GTR was performed in 122, and 21 underwent less than GTR. QoL was assessed at a mean of 7.7 yr after surgery (interquartile range: 5.7-9.6). Patients who underwent GTR had smaller tumors; otherwise, there were no baseline differences between groups. Patients who underwent GTR, after multivariable adjustment for baseline features and facial nerve and hearing outcomes, reported statistically significantly better Short Form Health Survey-36 (SF-36) physical and mental scores, Patient-Reported Outcomes Measurement Information System (PROMIS-10) physical and mental scores, and Penn Acoustic Neuroma Quality of Life (PANQOL) facial, energy, general health, and total scores compared to patients receiving less than GTR. CONCLUSION GTR is associated with better QoL using the general QoL measures SF-36 and PROMIS-10 and the disease-specific PANQOL, even after controlling for baseline and outcome differences. This is especially significant in the assessment of mental health, indicating there may indeed be a psychological advantage to the patient that translates to overall well-being to have the entire tumor removed if microsurgical resection is undertaken.
A comparison of the diagnostic accuracy of magnetic resonance imaging to axillary ultrasound in the detection of axillary nodal metastases in newly diagnosed breast cancer
Assing, Matthew A., Patel, Bhavika , Karamsadkar, Neel, Weinfurtner, Jared, Kiluk, John V. , Drukteinis, Jennifer S. , Usmani, Omar S. , Patel, Bhavika K

Mayo Clinic

The Breast Journal | April 10, 2017 | Volume: 23 | Issue: 6 | Pages: 647-655

10.1111/tbj.12812 | PMID 28397344 Get It

Severity of Preoperative Proteinuria is a Risk Factor for Overall Mortality in Patients Undergoing Nephrectomy
Yang, David Y. , Thompson, R. Houston, Zaid, Harras B. , Lohse, Christine M. , Boorjian, Stephen A. , Leibovich, Bradley C. , Cheville, John C. , Tollefson, Matthew K. , Rule, Andrew D. , Yang Md, David

Mayo Clinic

Journal of Urology | April 8, 2017 | Volume: 198 | Issue: 4 | Pages: 795-802

10.1016/j.juro.2017.04.016 | PMID 28396181 Get It

Microsurgery for Recurrent Vestibular Schwannoma After Previous Gross Total Resection
Perry, Avital , Graffeo, Christopher S. , Copeland, William R., Carlson, Matthew L. , Neff, Brian A., Driscoll, Colin L. W., Link, Michael J.

Mayo Clinic

Otology & Neurotology | April 7, 2017 | Volume: 38 | Issue: 6 | Pages: 882-888

10.1097/mao.0000000000001402 | PMID 28595258 Get It

Objective: To present a single-institution experience and supportive systematic literature review examining outcomes after repeat microsurgery for recurrent vestibular schwannoma (VS) following previous gross total resection (GTR). Study Design: Retrospective review of prospectively maintained VS database. Systematic literature review. Setting: Tertiary referral center. Patients: Six proven VS recurrences after primary GTR, treated via repeat microsurgery. Intervention: Repeat microsurgery. Main Outcome Measures: Facial nerve function, extent-of-resection, time-to-repeat surgery, same versus alternate approach at repeat surgery (relative to primary operation). Results: GTR was achieved in four (67%). House–Brackmann (HB) grade I–II facial nerve function was achieved in five (87%), including one that improved from preoperative HB grade V. An alternate surgical approach was chosen in four (67%). Systematic review identified four studies documenting 50 cases with patient-specific outcomes after repeat microsurgery for recurrent VS. Our cohort had significantly longer mean time-to-repeat surgery (117 vs. 64 months, p = 0.03), was significantly less likely to have HB III–VI function postrepeat (17% vs. 68%, p = 0.04), and was significantly less likely to undergo same approach surgery (33% vs. 90%, p = 0.0002); rates of GTR were nonsignificant (67% vs. 94%, p = 0.1). Conclusion: We report a six-patient series of microsurgery for recurrent VS after GTR, and the first systematic review of this rare and challenging entity. Anecdotally, our findings suggest that an alternate surgical approach may facilitate easier access to the tumor, with less scar encountered during the approach. Our results confirm that repeat microsurgery for recurrent VS is safe and effective, even for larger tumors not typically amenable to stereotactic radiosurgery.